药物发现市场中的人工智能Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease, Others); By Application; By Regions; Segment Forecast, 2021 - 2028

Report Summary

The global artificial intelligence (AI) in the drug discovery market was valued at USD 571.1 million in 2020 and is growing at a CAGR of 28.3% during the forecast period. The growing need for decreasing the cost of drug discovery and its approval process requires a lot of human expertise and time, which could be eased out with the help ofartificial intelligence.

Know more about this report:请求样本页面

据估计，药物开发和发现的平均成本约为26亿美元。这主要是由于不同疾病适应症的强烈批准过程，这消除了临床前和I期试验中的大多数药物候选者。为了反击失败，全球的制药巨头专注于人工智能工具，以实现更快和成本效益的药物发现。

行业动态

增长司机
小分子筛选和临床前研究期间产生的大量数据导致了药物发现过程中的人工智能（AI）。通过科学文学审查研究人员的市场数据是一种巨大和耗时的任务。在这种约束下，人工智能（AI）提高了筛选过程并减少了鉴定药物分子相互作用和细胞机制的时间。

在药物发现中，人工智能（AI）上升使用的另一个重要方面是根据需要进行数据挖掘和一系列具体定制的选择范围广泛。此外，人工智能（AI）的进步，如机器学习和人工神经网络，使Pharma公司能够以最高精度识别药物的结合性质。

The preclinical process is one of the important areas, accounting for high revenue loss and low returns. Here, artificial intelligence (AI)-based models are used for accurate analysis as compared with the standard animal models. These models help researchers in eliminating experiment costs and help in the prediction of differences in cross-species.

药物发现市场中的人工智能

该市场主要根据申请，治疗区域和地理区域进行分段。

By Application	通过治疗区域	By Regions
药物优化和重新估算 Preclinical testing 其他	Oncology Neurodegenerative Diseases 心血管疾病 代谢疾病 Infectious Disease 其他	North America (U.S., Canada) Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria) Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea) 拉丁美洲(巴西、墨西哥、基于“增大化现实”技术gentina) Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report:请求样本页面

Insight by Application

在类型的基础上，药物发现市场的全球人工智能被分散为药物优化和重新施加，临床前测试等。2020年，药物优化和重新展开市场分部占最大的收入份额。这一高度归因于人工智能（AI）工具提供了分析药物副作用及其对人体不良事件的有效方法的能力。

Moreover, such artificial intelligence (AI) platforms are also being used in deducing alternative applications for the existing drugs, which will enable pharma firms in diversifying the portfolio of their offerings and assist in devising alternate therapies to alteration in drug’s mechanism of action.

However, the pre-clinical testing market segment is projected to witness a lucrative artificial intelligence in the drug discovery market growth rate over the study period. This is attributed to their effectiveness in reducing experimental costs and other overheads.

例如，基于人工智能（AI）的平台Benchsci的机器学习平台旨在减少不同实验组的科学家的错误和帮助。同样，另一个AI系统“Euretos”使科学家能够通过硅工具进行设计实验，降低了更大程度的实验成本。

地理概述

North America artificial intelligence in the drug discovery market accounted for the highest revenue share in 2020. Key regional factors contributing to the market growth include the high adoption of artificial intelligence (AI) platforms among several pharma firms in the U.S. and the presence of well-established clinical infrastructure with sound funding capacity. According to the survey done by RELX, the establishment of artificial intelligence (AI) in companies has increased to 73 percent in 2019.

This was primarily due to the positive perception of artificial intelligence (AI) platforms among drug discovery market companies. Asia Pacific market is expected to witness a lucrative artificial intelligence in the drug discovery market growth rate over the assessment period.

The growing adoption of artificial intelligence (AI) systems in both India and China for drug development and a strong focus on pharma companies in boosting their capacities have driven the artificial intelligence (AI) systems for drug discovery in the concerned region.

Competitive insights

Some of the major players operating in the market for artificial intelligence (AI) in drug discovery include IBM Watson, Alphabet (DeepMind), Exscientia, GNS Healthcare, Insitro, BioSymetrics, Euretos, Berg Health, Benevolent AI, Atomwise, and Cyclica. Big pharmaceutical players in the industry are focusing on collaboration to stay competitive.

例如，在2021年1月，拜耳与人工智能（AI）药物发现公司exscientia的协作协议，以识别心血管和肿瘤疾病的新颖和毒品候选者。这将可能加快药物发现过程，其开发，成本和周转时间。伙伴关系将通过基于AI的算法专注于早期研究。